{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:02:43Z","timestamp":1782932563065,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jjcc.2023.04.005","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T02:13:57Z","timestamp":1680833637000},"page":"57-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["High- versus low-dose losartan and uric acid: An analysis from HEAAL"],"prefix":"10.1016","volume":"82","author":[{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Kiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin A.","family":"Konstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2023.04.005_bb0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semnephrol.2011.08.007","article-title":"Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options","volume":"31","author":"Doehner","year":"2011","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2015.08.109","article-title":"Regulation of uric acid metabolism and excretion","volume":"213","author":"Maiuolo","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0015","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cardfail.2020.08.015","article-title":"Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors","volume":"26","author":"Packer","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0020","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.amjcard.2014.09.008","article-title":"Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial)","volume":"114","author":"Vaduganathan","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0025","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0030","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","article-title":"Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies","volume":"105","author":"Doehner","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0035","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604","article-title":"Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study","volume":"3","author":"Ogino","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0045","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/ejhf.1984","article-title":"Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF","volume":"22","author":"Selvaraj","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0050","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0055","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ejhf.2433","article-title":"Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF","volume":"24","author":"McDowell","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dom.14559","article-title":"Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial","volume":"24","author":"Ferreira","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0065","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/00004872-200110000-00021","article-title":"Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout","volume":"19","author":"W\u00fcrzner","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0070","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/10641963.2014.933968","article-title":"Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study","volume":"37","author":"Matsumura","year":"2015","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0075","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/ndt\/gfs574","article-title":"Functional cooperation of URAT1 (SLC22A12) and URATv1 (SLC2A9) in renal reabsorption of urate","volume":"28","author":"Nakanishi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0080","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/ajh.2008.245","article-title":"Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients","volume":"21","author":"Hamada","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0085","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0090","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1053\/euhj.1998.1188","article-title":"Uric acid in chronic heart failure: a marker of chronic inflammation","volume":"19","author":"Leyva","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2023.04.005_bb0095","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","article-title":"Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Mackenzie","year":"2022","journal-title":"Lancet"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508723000680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508723000680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:08:20Z","timestamp":1760274500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508723000680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0914508723000680"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2023.04.005","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High- versus low-dose losartan and uric acid: An analysis from HEAAL","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2023.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}